Navigation Links
Global Apoptosis Industry
Date:11/8/2011

NEW YORK, Nov. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Apoptosis Industry

http://www.reportlinker.com/p0681917/Global-Apoptosis-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

This report analyzes the worldwide markets for Apoptosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 114 companies including many key and niche players such as Abbott Laboratories, AbGenomics International, Inc., Aegera Therapeutics, Inc., Amgen, Inc., Anavex Life Sciences Corporation, ApopLogic Pharmaceuticals Inc., Ascenta Therapeutics, ArQule, Inc., Bioniche Life Sciences, Inc., Celgene Corporation, Chroma Therapeutics Ltd., Cancer Research Technology Ltd., EntreMed, Inc., EpiCept Corporation, Exelixis Inc., Genextra S.p.A, Genta, Inc., Infinity Pharmaceuticals Inc., ISIS Pharmaceutical Inc., Novartis Ltd., Pfizer, Inc., Pharmacyclics, Inc., S*BIO Pte Ltd., S*BIO Pte Ltd, TopoTarget A/S, Xigen SA, and AEterna Zentaris GmbH. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 4

Apoptosis: A Natural Part of Cell Lifecycle 4

The Cell Death Pathway: A Review 4

Apoptosis Modulating Drugs All Set for Commercial Stage

Competition 5

Table 1: Apoptosis Drugs Pipeline Scenario Worldwide (2008):

Percentage Share Breakdown of Number of Apoptosis Modulating

Drugs in Development by Development Stage (includes

corresponding Graph/Chart) 6

R&D Scenario 6

Table 2: Apoptosis R&D Scenario Worldwide (2010): Percentage

Share Breakdown of Number of Apoptosis Modulating Drugs in

Development by Treatment Area (includes corresponding

Graph/Chart) 7

Table 3: Apoptosis Drug Development Worldwide (2010):

Percentage Share Breakdown of Number of Apoptosis Modulating

Drugs in Development by Agent Type (includes corresponding

Graph/Chart) 7

Table 4: Top Nations for Apoptosis Research (2011):

Breakdown of Number of Researchers Involved in Apoptosis

Research by Country (includes corresponding Graph/Chart) 8

Popular Classes of Molecules Influencing the Apoptotic

Process: A Review 8

Noteworthy Molecular Targets for Apoptosis 8

Death Receptors 8

Caspases 9

IAPs and SMAC 9

Bcl-2 proteins 9

p53 9

Table 5: Apoptosis Drugs Pipeline Worldwide (2010):

Percentage Share Breakdown of Number of Apoptosis

Modulating Agents in Development by Molecular Target 9

HSP90: A Popular Gene Target for Apoptosis 10

Apoptosis: The Key to Cutting Edge Cancer Treatment/Therapies 10

Table 6: Apoptosis R&D in Cancer Treatment (2010):

Percentage Share Breakdown of Number of Apoptosis Modulating

Drugs in Development by Type of Cancer (includes

corresponding Graph/Chart) 11

Focus on Targeted Therapy Bodes Well for Apoptosis-Targeted

Therapies for Cancer 11

Overcoming Therapy/Drug Resistance: A Major Business Case for

Direct Apoptogens 12

Factors Encouraging Investments in Apoptosis Based Cancer Drugs 12

Rise in Cancer Incidences Fosters Growth in Cancer Related

Apoptosis Research 12

Low Entry Barriers in Cancer Research Encourages Cancer

Related Apoptosis Research 13

Government Funded Investments Bode Well for Cancer Related

Apoptosis Research 13

High Prices/Efficacy Encourage Pharmas in Pushing

Commercialization of Apoptosis-Based Anticancer Drugs 14

Kinase Inhibitors: Cutting Edge Second Generation of Indirect

Apoptogens 14

Table 7: World Market for Kinase Inhibitors (2010):

Breakdown of Sales (In US$ Million) of Key Kinase Inhibitor

Drugs (includes corresponding Graph/Chart) 15

Outlook 15

3. APOPTOSIS: A CONCEPTUAL OVERVIEW 16

Apoptosis: Definition 16

Importance of Apoptosis 16

Apoptosis Mechanism 17

Execution of Apoptosis 17

Dead Cell Removal 18

Apoptosis & Diseases 18

Faulty Apoptotic Pathways 18

Cancer 18

Non-Cancer Diseases 18

Neurodegeneration 19

Liver Diseases 19

Heart Diseases 19

Autoimmune Diseases 19

Categories of Apoptogens in the Marketplace 20

First Generation Indirect Apoptogens (IAs) 20

Second Generation Indirect Apoptogens (IAs) 20

Direct Apoptogens 20

How Apoptosis is Targeted in Disease Research 20

Role of Death Receptors in Apoptosis 21

TNF Receptor Signaling 21

Signaling by Fas (CD95) 21

Apoptosis Induction by TRAIL 22

Caspase Inhibitors & Activators 22

Role of Intrinsic (Mitochondrial) Death Pathways in Apoptosis 22

Bcl-2 Family Proteins 23

Targeting Mitochondria Directly 23

Role of IAPs (inhibitors of apoptosis proteins) in Apoptosis

Regulation 23

Tumor Suppressor p53 24

4. DRUG APPROVALS, INTRODUCTIONS AND CLINICAL TRIALS 25

Cleveland BioLabs Pre-Clinical Data Demonstrates Anticancer

Effect of CBLB502 25

Senesco Technologies Files for IND for SNS01-T 25

Celgene Corporation Receives FDA approval for Priority Review

of sNDA for ISTODAX® 25

IntelliCyt Introduces a Suite of Assay Kits for Apoptosis

Screening 25

Vitamin E Tocotrienol Found to Increase Cancer Cell Apoptosis

Without Toxicity 26

Protectan Technology May Lead to Drugs That Mitigate Effects

of Radiation Exposure 26

VisEn Partners with MosaMedix to Introduce Annexin-Vivo 750

Imaging Agent for Monitoring Programmed Cell Death 26

AnaSpec Introduces Z-Fish Antibodies 27

Rexahn Pharmaceuticals Publishes Preclinical Research Data of

Quinoxalinyl-Piperazine Compounds 27

Aegera Therapeutics Completes the Phase I Study of AEG35156/

Sorafenib Combination 27

Amgen Announces Phase II Results of Clinical Studies of AMG 479 27

ArQule Announces Commencement of Phase II trial of ARQ 197 by

Kyowa Hakko Kirin 28

ArQule Announces Daiichi Sankyo Plans to Move Ahead with Phase

III clinical trial of ARQ 197 28

Celgene International Releases the Phase II Trial Data of

ISTODAX® in Treatment of PTCL 28

Romidepsin (FK228/depsipeptide) Successfully completes Phase I

clinical Trial 28

S*BIO Announces Results of Phase I trial for SB939 for

Hematologic Malignancies 29

EntreMed Publishes the Phase II Pre Clinical Results of ENMD-2076 29

Eli Lilly Concludes Phases II trials for LY2181308 in Myeloid

Leukaemia 29

Abbott to Present Data On Four Investigational Compounds 29

Can-Fite BioPharma to Commence the Phase I/II Clinical Trial

with CF102 30

TetraLogic Announces Inclusion of Pfizer Ventures into the

Series C Investors Syndicate 30

DiaTech Oncology Files Patent for MiCK (Microculture Kinetic)

Assay 30

Gloucester Pharma Intends to Discuss About New Drug

Application for Romidepsin 30

Cleveland BioLabs, Inc. Receives First Patent In the US 30

Daiichi Sankyo Commences Phase II Clinical Trials of CS-1008 31

5. RECENT INDUSTRY ACTIVITY 32

Cephalon to Take Over Gemin X 32

Amarantus BioSciences Enters into Licensing Agreement with

Generex Biotechnology 32

Celgene Takes Over Gloucester Pharmaceuticals 32

Sanofi Signs Research and Development Agreement with Ascenta 33

BIOCIUS Life Sciences Collaborates with BlueSky Biotech for

Providing Validated Enzymes 33

Ascenta Therapeutics Signs Agreement with Leukemia & Lymphoma

Society 33

Ascenta Therapeutics Collaborates with Ascentage Pharma Group 34

Aposense and Roche Ink Collaboration Agreement 34

Conatus Takes Over Idun 34

Cancer Research Technology Enters into Licensing Deal with ValiRx 35

Scancell Holdings Signs Licensing Agreement with University of

Nottingham 35

D-Pharm Collaborates with Wanbang Biopharmaceuticals 35

ACEA Biosciences, Roche and Vivo Biosciences Enter into

Collaboration 36

Infinity and Mundipharma Enter Into Global Alliance 36

Sigma-Aldrich and Highlands Stable Isotope Corporation Enter

into an Agreement 36

EntreMed, Inc. Enters Into Security Purchase Agreement with

Group of Strategic Investors 36

IBA Signs Collaboration Agreement with Aposense 37

Clinical Data and CombinatoRx Sign Partnership and Licensing

Agreement 37

FASgen and Centocor Ink Research and License Agreement 38

Graceway Pharmaceuticals Obtains Global Rights for GS 9191

Molecule 38

Æterna Zentaris Signs an Agreement with Sanofi-Aventis 38

6. FOCUS ON SELECT PLAYERS 39

Abbott Laboratories (USA) 39

AbGenomics International, Inc. (USA) 39

Aegera Therapeutics, Inc. (Canada) 39

Amgen, Inc. (USA) 40

Anavex Life Sciences Corporation (USA) 40

ApopLogic Pharmaceuticals Inc. (USA) 40

Ascenta Therapeutics (USA) 40

ArQule, Inc. (USA) 41

Bioniche Life Sciences, Inc. (Canada) 41

Celgene Corporation (USA) 41

Chroma Therapeutics Ltd (UK) 41

Cancer Research Technology Ltd. (UK) 41

EntreMed, Inc. (USA) 42

EpiCept Corporation (USA) 42

Exelixis Inc. (USA) 42

Genextra S.p.A. (Italy) 42

Genta, Inc. (USA) 43

Infinity Pharmaceuticals Inc. (USA) 43

ISIS Pharmaceutical Inc. (USA) 43

Novartis Ltd. (Switzerland) 43

Pfizer, Inc. (USA) 44

Pharmacyclics, Inc. (USA) 44

S*BIO Pte Ltd. (Singapore) 44

Theraptosis SA (France) 45

TopoTarget A/S (Denmark) 45

Xigen SA (Switzerland) 45

AEterna Zentaris GmbH (Germany) 45

7. GLOBAL MARKET PERSPECTIVE 46

Table 8: World Recent Past, Current and Future Analysis for

Apoptosis Modulators in Oncology - Analyzed with Annual Sales

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 46

Table 9: World Historic Review for Apoptosis Modulators in

Oncology by Region/Country - Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 47

8. THE UNITED STATES 48

A.Market Analysis 48

Current & Future Analysis 48

Overview 48

High Incidence of Pancreatic Cancer Drives Demand for

Apoptosis Modulators in US Market 48

Drug Approvals, Introductions & Clinical Trials 48

Recent Industry Activity 52

Key Players 55

B.Market Analytics 59

Table 10: US Recent Past, Current and Future Analysis for

Apoptosis Modulators in Oncology - Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 59

Table 11: US Historic Review for Apoptosis Modulators in

Oncology - Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 60

9. CANADA 61

A.Market Analysis 61

Current & Future Analysis 61

Clinical Trials 61

Recent Industry Activity 61

Key Players 61

B.Market Analytics 62

Table 12: Canadian Recent Past, Current and Future Analysis

for Apoptosis Modulators in Oncology - Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 62

Table 13: Canadian Historic Review for Apoptosis Modulators

in Oncology - Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 63

10. EUROPE 64

A.Market Analysis 64

Current & Future Analysis 64

Clinical Trials 64

B.Market Analytics 65

Table 14: European Recent Past, Current and Future Analysis

for Apoptosis Modulators in Oncology by Region/Country -

France, Germany, Italy, UK, Spain and Rest of Europe Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2009 through 2017 (includes corresponding Graph/Chart) 65

Table 15: European Historic Review for Apoptosis Modulators

in Oncology by Region/Country - France, Germany, Italy, UK,

Spain and Rest of Europe Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 66

Table 16: European 15-Year Perspective For Apoptosis

Modulators in Oncology by Region/Country - Percentage

Breakdown of Revenue for France, Germany, Italy, UK, Spain

and Rest of Europe Markets for Years 2003, 2010 and 2017

(includes corresponding Graph/Chart) 67

10a. FRANCE 68

A.Market Analysis 68

Current & Future Analysis 68

Theraptosis SA - A Key French Player 68

B.Market Analytics 69

Table 17: French Recent Past, Current and Future Analysis

for Apoptosis Modulators in Oncology - Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 69

Table 18: French Historic Review for Apoptosis Modulators in

Oncology - Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 70

10b. GERMANY 71

A.Market Analysis 71

Current & Future Analysis 71

Æterna Zentaris GmbH - A Key German Player 71

B.Market Analytics 72

Table 19: German Recent Past, Current and Future Analysis

for Apoptosis Modulators in Oncology - Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 72

Table 20: German Historic Review for Apoptosis Modulators in

Oncology - Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 73

10c. ITALY 74

A.Market Analysis 74

Current & Future Analysis 74

Genextra S.p.A. - A Key Italian Player 74

B.Market Analytics 75

Table 21: Italian Recent Past, Current and Future Analysis

for Apoptosis Modulators in Oncology - Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 75

Table 22: Italian Historic Review for Apoptosis Modulators

in Oncology - Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 76

10d. The UNITED KINGDOM 77

A.Market Analysis 77

Current & Future Analysis 77

Recent Industry Activity 77

Key Players 77

B.Market Analytics 78

Table 23: UK Recent Past, Current and Future Analysis for

Apoptosis Modulators in Oncology - Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 78

Table 24: UK Historic Review for Apoptosis Modulators in

Oncology - Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 79

10e. SPAIN 80

Market Analysis 80

Table 25: Spanish Recent Past, Current and Future Analysis

for Apoptosis Modulators in Oncology - Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 80

Table 26: Spanish Historic Review for Apoptosis Modulators

in Oncology - Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 81

10f. REST OF EUROPE 82

A.Market Analysis 82

Current & Future Analysis 82

Key Players 82

B.Market Analytics 83

Table 27: Rest of Europe Recent Past, Current and Future

Analysis for Apoptosis Modulators in Oncology - Analyzed

with Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 83

Table 28: Rest of Europe Historic Review for Apoptosis

Modulators in Oncology - Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 84

11. ASIA-PACIFIC 85

A.Market Analysis 85

Current & Future Analysis 85

Clinical Trials 85

Recent Industry Activity 85

Key Player 87

B.Market Analytics 87

Table 29: Asia-Pacific Recent Past, Current and Future

Analysis for Apoptosis Modulators in Oncology - Analyzed

with Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 87

Table 30: Asia-Pacific Historic Review for Apoptosis

Modulators in Oncology - Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 88

12. LATIN AMERICA 89

A.Market Analysis 89

Current & Future Analysis 89

Recent Industry Activity 89

B.Market Analytics 90

Table 31: Latin America Recent Past, Current and Future

Analysis for Apoptosis Modulators in Oncology - Analyzed

with Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 90

Table 32: Latin America Historic Review for Apoptosis

Modulators in Oncology - Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 91

13. REST OF WORLD 92

A.Market Analysis 92

Current & Future Analysis 92

Clinical Trials 92

Recent Industry Activity 92

B.Market Analytics 93

Table 33: Rest of World Recent Past, Current and Future

Analysis for Apoptosis Modulators in Oncology - Analyzed

with Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 93

Table 34: Rest of World Historic Review for Apoptosis

Modulators in Oncology - Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 94

COMPETITIVE LANDSCAPE

Total Companies Profiled: 114 (including Divisions/Subsidiaries - 123)

Region/Country Players

The United States 74

Canada 4

Japan 4

Europe 30

France 3

Germany 6

The United Kingdom 7

Italy 2

Spain 1

Rest of Europe 11

Asia-Pacific (Excluding Japan) 7

Middle East 4

To order this report:

Genomics Industry: Global Apoptosis Industry

Genomics Business News

More  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Global Biochip Markets: Microarrays and Lab-on-a-Chip
2. Eppendorf AG Deploys a Strategic Information Management Solution on a Global Level
3. Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
4. Informex Introduces a Thorough Global Pharma Perspectives Conference
5. Global Automated And Rapid Microbiological Tests Industry
6. BioStorage Technologies to Host Global Sample Management Benchmarking Symposium at International Contract Services Expo
7. United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report
8. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
9. Nanobiotechnology: Applications and Global Markets
10. Breakthrough in Preventing Food-borne Illnesses Wins $20,000 Grand Prize in Global Design Contest
11. Global Biotechnology Instrumentation Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant ... report, "Stem Cell Research Products, Opportunities, Tools, and Technologies ... ... in the stem cell industry, BioInformant has more than ... the stem cell market, by stem cell type. This ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection ... American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:2/1/2016)...  Today, the first day of American Heart Month, ... a first of its kind workplace health solution that ... the first application of Watson ... and Welltok will create a new offering that combines ... delivered on Welltok,s health optimization platform. The effort is ...
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
Breaking Biology News(10 mins):